Jarrel Quansah’s move to Bayer Leverkusen removed what little cover Arne Slot had for this position. Virgil van Dijk and Ibrahima Konaté form a formidable first-choice pairing, but the injury-prone ...

Small bands of Russian soldiers thrust deeper into eastern Ukraine on Tuesday before a summit between Russian President ...

With a packed pipeline of drug candidates targeting multiple markers of cancer, Bayer AG signed on for a new project, this ...

After 23 goals and 24 assists in 142 appearances across all competitions for Bayer Leverkusen during a four year spell, Amine ...

Fenway Park concession workers are taking their labor dispute across the Atlantic in hopes of a face-to-face meeting with Red ...

After 23 goals and 24 assists in 142 appearances across all competitions for Bayer Leverkusen during a four year spell, Amine ...

After securing Ernest Poku’s transfer, Bayer Leverkusen are continuously looking to strengthen their squad for the 2025/26 ...

Bayer will partner with Kumquat Biosciences to develop Kumquat’s KRAS G12D inhibitor, which could generate $1.3 billion-plus for the San Diego biotech.

After securing Ernest Poku’s transfer, Bayer Leverkusen are continuously looking to strengthen their squad for the 2025/26 ...

Kumquat, based in San Diego, received US Food and Drug Administration clearance of its investigational new drug application for the KRAS G12D inhibitor in July. The firm will be responsible for ...

The German pharma will license a KRAS G12D inhibitor from Kumquat Biosciences. Elsewhere, a Biohaven OCD drug missed its ...

German pharmaceutical giant Bayer said Tuesday it had struck a deal valued at up to $1.3 billion (1.1 billion euros) with a US-based biotech company to develop its prospective cancer drug.